RankAlpha logo
Back to Rankings

ANIK

Anika TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Primary filing evidence supports a cautious constructive setup: Q1 showed 13% revenue growth, gross margin expansion to 64%, and continued progress on both Hyalofast and Cingal, which keeps the core commercial-plus-pipeline thesis intact [#SEC-10Q-2026-04-30].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Cash and cash equivalents declined to $41.0 million at March 31, 2026, while net cash used in operating activities was $4.8 million in Q1 [#SEC-10Q-2026-04-30].
Momentum
82
Value
61
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $20.00 · Bear $12.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-13 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-12 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $17.50
Why
Momentum82 · Δ7d -3.2
Value61 · Δ7d -0.0
Sentiment54 · Δ7d +2.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
82
26% active weight
Current posture
7d trendImproving
Δ7d
-3.2
Δ21d
-1.4
Value
61
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
54
34% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
+7.5
Why this grade

Composite grade A. Momentum 82.0 / Value 61.2 / Sentiment 53.8

Fundamentals (TTM)
As of 2026-07-13
Market Cap
$209.83M
Beta
0.43
Shares Out
13.31M
P/E (TTM)
10.1
P/S (TTM)
1.66
P/FCF (TTM)
210.75
Rev YoY
+13.2%
EPS YoY
+9.7%
Gross Margin
+58.6%
Op Margin
+19.6%
Net Debt
-$31.23M
Current Ratio
4.46
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology